United States · FDA National Drug Code directory

TRODELVY

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
55135-132_2085d741-19ba-4115-bbe9-0debac82c204
Product NDC
55135-132
Form
POWDER, FOR SOLUTION
Composition / generic term
SACITUZUMAB GOVITECAN
Labeler
Gilead Sciences, Inc.
Marketing category
BLA
Marketing start / end (source format)
20200422
Source listing expiry
20271231

Source-listed ingredients

  • SACITUZUMAB GOVITECAN — 180 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 1 VIAL in 1 BOX (55135-132-01) / 1 POWDER, FOR SOLUTION in 1 VIAL · 55135-132-01

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →